The San Francisco startup Loyal has developed a new drug, LOY-002, which aims to extend the healthy lifespan of dogs without requiring dietary restrictions. Currently undergoing trials on approximately 1,300 dogs across 70 veterinary clinics in the United States, early results suggest it may add at least one year to a dog's life. The drug has recently passed its second safety review by the U.S. Food and Drug Administration (FDA) in January 2026. Online reactions to the announcement have been varied; while many dog owners express excitement at the prospect of prolonging their pets' lives, others question the scientific validity and intentions behind such a product. Comments range from humorous to critical, reflecting a deep emotional connection between pet owners and their dogs, as well as concerns about commercialization in pet care. The ongoing trials will determine the drug's effectiveness before any broader claims can be made.